PDCD1 and neoplasm: The tracer was tested in mice xenografted with CT26 cancer cells, which showed that the peptide is eliminated renally and that the uptake in the tumor is predictive for therapy response with anti-PD-1 and anti-CTLA-4 combination therapy [24].